Citadel Advisors’s Theratechnologies THTX Stock Holding History

Citadel Advisors’s Portfolio THTX Stock Details THTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,250	Closed	-$59.6K	–	14110
2025 Q2	$59.6K	Buy	+25,250	New	+$61.9K	﹤0.01%	11681
2025 Q1	–	Sell	-17,317	Closed	-$31.3K	–	15560
2024 Q4	$31.3K	Sell	17,317 -20,825	-55%	-$28.3K	﹤0.01%	12834
2024 Q3	$46.9K	Buy	+38,142	New	+$51.7K	﹤0.01%	11981
2024 Q2	–	Sell	-19,572	Closed	-$31.9K	–	15400
2024 Q1	$31.9K	Sell	19,572 -9,119	-32%	-$14.6K	﹤0.01%	12635
2023 Q4	$46.5K	Buy	+28,691	New	+$43.2K	﹤0.01%	11851

Other funds holding THTX

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

CWP

Cyndeo Wealth Partners St. Petersburg, Florida $1.9B AUM 24.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GIP

Greatmark Investment Partners Columbus, Georgia $854M AUM 15.72% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Citadel Advisors's THTX Position: Q3 2025 in Review

Citadel Advisors sold out of Theratechnologies (THTX) in Q3 2025, closing a stake of 25,250 shares — an estimated $59.6K sold.

Citadel Advisors first reported a position in THTX in Q4 2023 and held it in 5 quarters. The position peaked at $59.6K in Q2 2025. 10 funds tracked by Wall St. Rank hold THTX as of Q3 2025.

Citadel Advisors reported no remaining Theratechnologies position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 25,250 Theratechnologies shares in Q3 2025, an estimated $59.6K.
Citadel Advisors first reported a position in Theratechnologies in Q4 2023 and held it in 5 quarters.
Citadel Advisors's Theratechnologies position peaked at $59.6K in Q2 2025.
10 funds tracked by Wall St. Rank held Theratechnologies as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.